Geode Capital Management, LLC has released its latest 13F-HR filing, detailing its investment holdings as of September 30, 2026. This filing is crucial for understanding the firm's investment strategies and portfolio adjustments in the competitive financial services industry.

Geode Capital Management, based in Boston, Massachusetts, is known for its active management approach in the asset management sector. The firm, incorporated in Delaware, has a fiscal year ending on December 31. Its recent filings include a 13F-HR on November 6, 2026, and a Schedule 13G/A on October 8, 2026, reflecting its ongoing commitment to transparency with investors and regulators.

The latest filing reveals a total of 8,379 entries with a reported total value of approximately $1.92 trillion. This substantial portfolio indicates Geode's strategic positioning in various sectors, showcasing its ability to adapt to market dynamics. The filing was signed by Laura Doherty, the Chief Operating Officer, emphasizing the firm's leadership in managing these investments.

Among the notable holdings, Geode has significant investments in companies such as 10X Genomics Inc and 3M Co, which highlight its focus on innovative and established industries. The firm’s investment discretion is marked as definitive, indicating a proactive management style.

This filing may impact various stakeholders, including investors looking to benchmark their portfolios against Geode's substantial holdings. Additionally, competitors in the asset management industry will analyze these positions for insights into market trends and strategic investment opportunities. The detailed nature of the filing allows for a comprehensive understanding of Geode's investment philosophy and market positioning.

Looking ahead, the filing does not specify any immediate next steps or upcoming votes related to these holdings. However, the firm’s ongoing commitment to transparency and regulatory compliance will likely continue to shape its future filings and investor relations strategies.